Enhance Recovery. Optimize ICU Resource Utilization.
See how PleuraFlow® Active Clearance Technology® can help free ICU resources and get patients home faster.
— ClearFlow Executives Comment on Need for New Protocols — Anaheim, CA – April 13, 2016—Clinical data presented at the Society of Cardiovascular Anesthesiologists (SCA) 2016 Annual Meeting and Workshops in San Diego last week indicated that Hospital Acquired Infections (HAI) are 75% more likely to occur in patients with interventions for Retained Blood Syndrome (RBS) after heart surgery than in patients who do not have RBS. All…
— ClearFlow Executive Comments on Possible Solutions to Hospital Acquired Infections — Anaheim, CA – April 6, 2016—Cardiac anesthesia investigators from Germany presented data revealing the role retained blood plays in hospital acquired infections after heart surgery this week at the Society of Cardiovascular Anesthesiologists (SCA) 2016 Annual Meeting and Workshops in San Diego, CA. Critical care specialists from Charité – Universitätsmedizin Berlin’s Department of Anesthesiology and Intensive…
Anaheim, CA – March 30, 2016—Cardiac Surgeons at the Montreal Heart Institute have published a report featured in this month’s Annals of Thoracic Surgery detailing how active clearance of chest tubes in the ICU non surgically treated a life-threatening episode of pericardial tamponade in a patient recovering from heart surgery (Annals of Thoracic Surgery, 101: 1159-1163, 2016). Affiliated with Université de Montréal in Quebec, the Montreal Heart Institute…
Designation recognizes the development of new solutions that benefit the healthcare industry WAYNE, N.J., March 29, 2016 /PRNewswire/ — Getinge Group announced its Maquet V8 Catheter and Maquet PleuraFlow Active Clearance Technology System have received Innovative Technology designation from Novation, the leading healthcare services company that serves the more than 100,000 members and affiliates of VHA Inc., UHC, Children’s Hospital Association, and Provista. The designation was based on…
Anaheim, CA – March 9, 2016—ClearFlow Inc., a medical device company based in Anaheim, California, has announced the publication of significantly positive results in a study evaluating the company’s PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) and Postoperative Atrial Fibrillation (POAF) among patients recovering from heart surgery was published in the March issue of the Journal of Thoracic and Cardiovascular…
Amsterdam, Netherlands – October 8, 2015—ClearFlow Inc., a medical device company based in Anaheim, California, USA, exhibited its innovative PleuraFlow® Active Clearance Technology® System at the 29th annual Association for Cardio-Thoracic Surgery (EACTS) meeting in Amsterdam this week. The EACTS Annual Meeting is the largest cardio-thoracic meeting in the world, a position it has maintained for over a decade, and this year’s event featured ClearFlow’s PleuraFlow technology for…
ClearFlow Participates in Clinical Panel Presentations and Round Table at Conference Focused on Clinical Impact of Retained Blood Washington, DC – October 6, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, participated in a series of panel presentations related to the subject of chest tube patency standards to prevent Retained Blood Syndrome (RBS) following cardiothoracic surgery last Friday at the Cardiovascular-Thoracic (CVT) Critical Care Conference in…
Anaheim, CA – June 03, 2015— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted expanded Indications for Use of the company’s patented PleuraFlow® Active Clearance Technology® System. The PleuraFlow System is a patented medical device that prevents chest drains from occluding with clot, which can lead to retained blood around the heart and…